Jain Global’s Pacira BioSciences PCRX Stock Holding History

Jain Global’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,906	Closed	-$337K	–	1276
2024 Q4	$337K	Buy	+17,906	New	+$314K	0.01%	534

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Jain Global's PCRX Position: Q1 2025 in Review

Jain Global sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 17,906 shares — an estimated $337K sold.

Jain Global first reported a position in PCRX in Q4 2024 and held it in 1 quarter. The position peaked at $337K in Q4 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

Jain Global reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
Jain Global sold 17,906 Pacira BioSciences shares in Q1 2025, an estimated $337K.
Jain Global first reported a position in Pacira BioSciences in Q4 2024 and held it in 1 quarter.
Jain Global's Pacira BioSciences position peaked at $337K in Q4 2024.
235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Jain Global's 13F filing for Q1 2025, filed 15 May 2025.